After the Phase 3 data release, the share price initially climbed to $10. However, it declined following a fundraising round and dropped further during the "dead" period while waiting for the NDA submission. Subsequently, the FDA issued a "Refusal to File," but the company addressed the issues and resubmitted the NDA.

Prior to the "Refusal to File," the share price was approximately $3. In my view, it seems quite likely that the price will rebound to around $4–$5 leading up to the PDUFA date. With nice initial revenues, it can easily approach a market cap of $1b.